Gubra (GUBRA) Panoramica del titolo
Gubra A/S, una società biotecnologica, si concentra sulla ricerca pre-clinica a contratto e sulla scoperta di farmaci a base di peptidi nell'ambito delle malattie metaboliche e fibrotiche in Europa, Nord America e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 2/6 |
| Crescita futura | 5/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 0/6 |
GUBRA Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Gubra A/S
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | DKK 311.80 |
| Massimo di 52 settimane | DKK 557.50 |
| Minimo di 52 settimane | DKK 290.20 |
| Beta | 0.31 |
| Variazione di 1 mese | -21.06% |
| Variazione a 3 mesi | -7.70% |
| Variazione di 1 anno | -26.81% |
| Variazione a 3 anni | 190.21% |
| Variazione a 5 anni | n/a |
| Variazione dall'IPO | 183.45% |
Notizie e aggiornamenti recenti
Nuova narrativa • Sep 04
Obesity And Metabolic Tailwinds Will Drive Powerful Long Term Upside Potential
Catalysts About Gubra Gubra focuses on peptide drug discovery, obesity and metabolic disease research, supported by an in-house CRO and venture investment platform. What are the underlying business or industry changes driving this perspective?Articolo di analisi • Aug 26
Analyst Forecasts For Gubra A/S (CPH:GUBRA) Are Surging Higher
Celebrations may be in order for Gubra A/S ( CPH:GUBRA ) shareholders, with the analysts delivering a significant...Articolo di analisi • Aug 23
Earnings Beat: Gubra A/S (CPH:GUBRA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Gubra A/S ( CPH:GUBRA ) missed earnings with its latest half-yearly results, disappointing overly-optimistic...
Aggiornamento narrativa • Aug 21
GUBRA: Early Obesity Trial Progress Will Support Long Term Upside
Analysts have lifted their fair value estimate for Gubra from DKK 451.50 to DKK 501.00. They cite updated assumptions for revenue growth, profit margin and future P/E as key drivers of the higher price target.
Nuova narrativa • Aug 21
Obesity Drug Partnerships And CRO Demand Will Support Steady Long-Term Prospects
Catalysts About Gubra Gubra is a peptide focused biotech and CRO company that develops obesity and metabolic drug candidates while providing preclinical research services to pharmaceutical and biotech clients. What are the underlying business or industry changes driving this perspective?Recent updates
Nuova narrativa • Sep 04
Obesity And Metabolic Tailwinds Will Drive Powerful Long Term Upside Potential
Catalysts About Gubra Gubra focuses on peptide drug discovery, obesity and metabolic disease research, supported by an in-house CRO and venture investment platform. What are the underlying business or industry changes driving this perspective?Articolo di analisi • Aug 26
Analyst Forecasts For Gubra A/S (CPH:GUBRA) Are Surging Higher
Celebrations may be in order for Gubra A/S ( CPH:GUBRA ) shareholders, with the analysts delivering a significant...Articolo di analisi • Aug 23
Earnings Beat: Gubra A/S (CPH:GUBRA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Gubra A/S ( CPH:GUBRA ) missed earnings with its latest half-yearly results, disappointing overly-optimistic...Aggiornamento narrativa • Aug 21
GUBRA: Early Obesity Trial Progress Will Support Long Term Upside
Analysts have lifted their fair value estimate for Gubra from DKK 451.50 to DKK 501.00. They cite updated assumptions for revenue growth, profit margin and future P/E as key drivers of the higher price target.Nuova narrativa • Aug 21
Obesity Drug Partnerships And CRO Demand Will Support Steady Long-Term Prospects
Catalysts About Gubra Gubra is a peptide focused biotech and CRO company that develops obesity and metabolic drug candidates while providing preclinical research services to pharmaceutical and biotech clients. What are the underlying business or industry changes driving this perspective?Aggiornamento narrativa • Jun 24
GUBRA: Upcoming Phase 2 Obesity Milestone Will Support Long Term Upside
Analysts have kept their DKK 451.50 price target for Gubra unchanged, citing only minor tweaks to the discount rate and future P/E assumptions, without a shift in their overall valuation view. What's in the News for Gubra Gubra highlighted that partner Boehringer Ingelheim plans to start Phase 2 clinical development in mid 2026 for BI 3034701, a potential first in class triple GLP-1, GIP and NPY2 receptor agonist peptide for obesity and related metabolic diseases, based on Gubra discovered technology.Aggiornamento narrativa • Jun 10
GUBRA: Phase 2 Obesity Candidate Progress Will Support Long Term Upside
Analysts have kept their DKK 451.50 price target for Gubra unchanged, citing only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and forward P/E assumptions. What's in the News Gubra highlighted that partner Boehringer Ingelheim plans to start Phase 2 clinical development in mid 2026 for BI 3034701, an investigational triple GLP-1, GIP and NPY2 receptor agonist peptide for obesity and related metabolic diseases.Aggiornamento narrativa • May 26
GUBRA: Obesity Pipeline Progress And Phase 2 Milestones Will Drive Long Term Upside
Analysts have trimmed their price target for Gubra from DKK 469.50 to DKK 451.50, citing slightly softer revenue growth expectations and a modestly lower projected profit margin. This is partly offset by a small reduction in the discount rate and a marginally lower future P/E assumption.Articolo di analisi • May 14
Analysts' Revenue Estimates For Gubra A/S (CPH:GUBRA) Are Surging Higher
Gubra A/S ( CPH:GUBRA ) shareholders will have a reason to smile today, with the analysts making substantial upgrades...Aggiornamento narrativa • Apr 27
GUBRA: Obesity Trial Pipeline Will Drive Long Term Upside
Analysts have kept their DKK 469.50 price target on Gubra unchanged, citing only minor tweaks to inputs such as discount rate, revenue growth, profit margin and forward P/E assumptions, rather than any shift in their overall view. What's in the News Gubra has called its annual general meeting for March 26, 2026, with the board proposing to renew and extend its authorization to issue warrants, including an increase of 120,277 warrants and an extension of the authorization period to March 26, 2031 (Key Developments).Aggiornamento narrativa • Apr 12
GUBRA: Obesity Study And Ventures Unit Will Drive Long Term Upside
Analysts have kept their DKK 469.5 price target on Gubra unchanged, citing only marginal adjustments to assumptions such as the discount rate and forward P/E as the basis for this maintained view. What's in the News Gubra submitted a clinical trial application in Germany for GUB-UCN2, a first in human Phase 1/2a study designed to assess safety, tolerability, pharmacokinetics and preliminary efficacy, including muscle volume and muscle function endpoints, in about 188 participants across multiple indications and patient groups (Key Developments).Aggiornamento narrativa • Mar 29
GUBRA: Obesity Trial And Ventures Expansion Will Drive Future Upside Potential
Analysts have kept their DKK price target for Gubra unchanged at DKK469.50, citing essentially stable assumptions on discount rate, revenue trajectory, profit margin and forward P/E as reasons to maintain their prior valuation view. What's in the News Clinical trial application submitted in Germany for GUB-UCN2, a first in human Phase 1/2a study targeting high quality weight loss, with about 188 participants across multiple indications and patient groups, including combination use with incretin based therapy for obesity (Product Related Announcement).Aggiornamento narrativa • Mar 15
GUBRA: Future Obesity Trial And Ventures Platform Will Drive Upside Potential
Analysts have kept their DKK 469.5 price target on Gubra unchanged, citing model adjustments that reflect a slightly higher discount rate, softer revenue expectations, a lower projected profit margin and a higher future P/E multiple. What's in the News Gubra submitted a clinical trial application in Germany for GUB-UCN2, a first in human Phase 1/2a study aimed at high quality weight loss, with a design that looks at safety, tolerability, pharmacokinetics, preliminary efficacy, muscle volume and muscle function in about 188 participants, including both healthy volunteers and people living with obesity, as a standalone therapy and in combination with incretin based treatment.Aggiornamento narrativa • Mar 01
GUBRA: Future Pipeline Milestones And Royalties Will Drive Upside Potential
Analysts have reduced their price target for Gubra from DKK 502.50 to DKK 469.50, reflecting updated views on discount rates, revenue contraction, profit margins and a significantly lower future P/E multiple. What's in the News Gubra plans an Analyst and Investor Day event, giving the market a closer look at its business model, pipeline and long term priorities (Key Developments).Aggiornamento narrativa • Aug 16
AbbVie Agreement And Clinical Trials Will Unlock New Avenues
The significant downward revision in Gubra’s consensus price target reflects lowered expectations for future growth and earnings, as evidenced by reduced forecasts for both revenue growth and the future P/E multiple, resulting in a new fair value estimate of DKK540. What's in the News Extraordinary cash dividend of DKK 1 billion (DKK 61.2 per share) approved at EGM.Articolo di analisi • Jun 28
Gubra A/S' (CPH:GUBRA) 35% Jump Shows Its Popularity With Investors
Gubra A/S ( CPH:GUBRA ) shares have had a really impressive month, gaining 35% after a shaky period beforehand...Nuova narrativa • May 16
AbbVie Agreement And Clinical Trials Will Unlock New Avenues
Strategic partnerships and collaborations with top pharma companies ensure sustainable revenue streams and growth opportunities for Gubra.Articolo di analisi • May 04
We're Not Worried About Gubra's (CPH:GUBRA) Cash Burn
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Articolo di analisi • Mar 11
Gubra A/S' (CPH:GUBRA) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Gubra A/S ( CPH:GUBRA ) shareholders that were waiting for something to happen have been dealt a blow with a 26% share...Articolo di analisi • Jan 14
We're Not Very Worried About Gubra's (CPH:GUBRA) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Articolo di analisi • Jun 19
Gubra A/S' (CPH:GUBRA) Shares Climb 25% But Its Business Is Yet to Catch Up
Gubra A/S ( CPH:GUBRA ) shareholders would be excited to see that the share price has had a great month, posting a 25...Articolo di analisi • Mar 07
Subdued Growth No Barrier To Gubra A/S (CPH:GUBRA) With Shares Advancing 60%
Despite an already strong run, Gubra A/S ( CPH:GUBRA ) shares have been powering on, with a gain of 60% in the last...Rendimenti per gli azionisti
| GUBRA | DK Life Sciences | DK Mercato | |
|---|---|---|---|
| 7D | -0.6% | 4.4% | 0.7% |
| 1Y | -26.8% | 5.7% | -1.5% |
Ritorno vs Industria: GUBRA ha avuto una performance inferiore rispetto al Danish Life Sciences che ha registrato un rendimento 5.7 % nell'ultimo anno.
Rendimento vs Mercato: GUBRA ha avuto una performance inferiore al mercato Danish che ha registrato un rendimento -1.5 % nell'ultimo anno.
Volatilità dei prezzi
| GUBRA volatility | |
|---|---|
| GUBRA Average Weekly Movement | 6.0% |
| Life Sciences Industry Average Movement | 5.7% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in DK Market | 7.2% |
| 10% least volatile stocks in DK Market | 2.2% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di GUBRA è stato volatile rispetto al mercato Danish.
Volatilità nel tempo: La volatilità settimanale ( 6% ) di GUBRA è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni Danish.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2008 | 330 | Markus Rohrwild | www.gubra.dk |
Gubra A/S, azienda biotecnologica, si concentra sulla ricerca pre-clinica a contratto e sulla scoperta di farmaci a base di peptidi nell'ambito delle malattie metaboliche e fibrotiche in Europa, Nord America e a livello internazionale. L'azienda opera attraverso tre segmenti: Ricerca pre-clinica a contratto (CRO), Scoperta e partnership e Gubra Green. Offre servizi di ricerca e sviluppo preclinico a contratto nell'ambito delle malattie metaboliche e fibrotiche per l'industria farmaceutica e biotecnologica, oltre a fornire servizi di farmacologia in vivo, saggi di biomarcatori, bioinformatica, sequenziamento next gen, farmacocinetica e istologia 2D e 3D con intelligenza artificiale.
Gubra A/S Riepilogo dei fondamenti
| GUBRA statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | DKK 5.12b |
| Utili (TTM) | -DKK 182.25m |
| Ricavi(TTM) | DKK 271.02m |
18.9x
Rapporto P/S-28.1x
Rapporto P/EGUBRA è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| GUBRA Conto economico (TTM) | |
|---|---|
| Ricavi | DKK 271.02m |
| Costo del fatturato | DKK 66.97m |
| Profitto lordo | DKK 204.05m |
| Altre spese | DKK 386.30m |
| Utili | -DKK 182.25m |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
Mar 03, 2027
| Utile per azione (EPS) | -11.10 |
| Margine lordo | 75.29% |
| Margine di profitto netto | -67.25% |
| Rapporto debito/patrimonio netto | 0% |
Come si è comportato GUBRA nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/18 11:47 |
| Prezzo dell'azione a fine giornata | 2026/09/18 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Gubra A/S è coperta da 3 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Rune Dahl | DNB Carnegie |
| Jesper Ilsøe | DNB Carnegie |
| Rajan Sharma | Goldman Sachs |